AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04685291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided block of the supraclavicular nerves
Description: The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
Study NCT04685291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pain management
Description: * oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~* In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)
Study NCT06140238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib administration 15 minutes before start surgical operation
Study NCT04584307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab 10-20mg/kg
Study NCT04584307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 2mg
Study NCT06140238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline administration 15 minutes before start surgical operation
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FH diagnosis program
Description: Uptake of screening, diagnosis, and initiation of care management for FH
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Develop and implement tools for quality monitoring
Description: EHR tools to order labs, record results, and document FH care
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Develop educational materials
Description: Education regarding guidelines for identification and treatment of FH
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Conduct educational outreach visits
Description: Continuing medical education (CME) material for FH that is presented to
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Intervene with clinicians and patients to enhance
Description: Notify patients simultaneously with clinicians about the need for screening
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions
Description: Clinical lipid champions
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Audit and provide feedback
Description: Provide aggregate level feedback to clinics on diagnosing FH
Study NCT06410638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walking Test
Description: It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.
Study NCT06410638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shuttle walking test
Description: Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
Study NCT06329115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
Study NCT05043285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection
Study NCT05284513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation strategy package: Stage implementation scale up
Description: Develop the timeline for the stepped-wedge rollout to primary care
Study NCT05043285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT05526209 — intervention group
Intervention type: PROCEDURE
Intervention: using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
Description: using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
Study NCT05645692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Participants will receive 1200 mg IV atezolizumab Q3W.
Study NCT05645692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive 600 mg IV tobemstomig Q3W.
Study NCT05645692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Participants will receive 600 mg IV tiragolumab Q3W.
Study NCT05669599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Maridebart Cafraglutide
Description: Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
Study NCT05669599 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Maridebart Cafraglutide
Description: Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
Study NCT05669599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo by SC injection.
Study NCT05669599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo by SC injection.
Study NCT05648214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)
Study NCT05648214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part B
Description: Administered by SC parallel single dose
Study NCT05648214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection
Study NCT05648214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PB)
Description: Administered by SC injection
Study NCT06509074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Pragmatic design. Any beta-blocker with alpha or NO activity may be used
Study NCT05453357 — intervention group
Intervention type: DEVICE
Intervention: iGlucose
Description: The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose.
Study NCT04867590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endorotor
Description: The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis.
Study NCT04867590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required.
Study NCT04932590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test
Description: The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
Study NCT06626802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Dilation + Topical Mitomycin
Description: Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)
Study NCT06626802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Dilation + Injection Triamcinolone
Description: Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
Study NCT06626867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Supplementation
Description: Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
Study NCT06626867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
Study NCT06627114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition education program
Description: Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress.
Study NCT06627114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.
Study NCT06627114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
Study NCT06626841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic floor muscles contractile capacity and activation
Description: An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis).
Study NCT06627946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP group
Description: Local anesthesia 0.25% bupivacine was administered in the TAP plane
Study NCT06627946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP group
Description: Local anesthesia 0.25% bupivacine was administered in the TAP plane
Study NCT04892615 — intervention group
Intervention type: DEVICE
Intervention: drainage tube was removed on 5th days after surgery.
Description: drainage tube was removed on 5th days after surgery.
Study NCT04892615 — intervention group
Intervention type: DEVICE
Intervention: drainage tube was removed on 7th days after surgery.
Description: drainage tube was removed on 7th days after surgery.
Study NCT05288972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mattress 1
Description: A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
Study NCT05288972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mattress 2
Description: A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
Study NCT05306574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection weekly for 52 weeks
Study NCT05306574 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection weekly for 52 weeks
Study NCT06003621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: 600mg IV every 21 days from Cycle 1 Day 1
Study NCT06003621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200mg IV every 21 days from Cycle 2 Day 1
Study NCT06087328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Nicotine patch and lozenge dose
Description: 1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
Study NCT06087328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Nicotine patch and lozenge dose
Description: 21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
Study NCT05709496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac
Description: 30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
Study NCT06563349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Description: Intraoperative intravenous magnesium sulfate infusion.
Study NCT06563349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Intraoperative intravenous normal saline infusion.
Study NCT05330546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Densah burs
Description: using Densah burs to prepare implant osteotomy
Study NCT05330546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge expansion screws
Description: using Ridge expansion screws to prepare implant osteotomy
Study NCT04706390 — intervention group
Intervention type: BIOLOGICAL
Intervention: covid-19 vaccine
Description: vaccination
Study NCT05272813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553
Study NCT05345249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride Injection
Description: Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
Study NCT05345249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Placebo comparator
Study NCT05235503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal cannabis in combination with oxycodon
Description: The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
Study NCT05235503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medicinal cannabis in combination with placebo oxycodon
Description: The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
Study NCT05314491 — intervention group
Intervention type: DEVICE
Intervention: Multigen Plus CCK
Description: Total Knee Arthroplasty
Study NCT05314491 — intervention group
Intervention type: DEVICE
Intervention: AMF TT cones
Description: To fill a proximal tibia or distal femur defect
Study NCT05785910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IUDS
Description: a battery of neuropsychological test
Study NCT05165589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveInsights accelerometer device
Description: Accelerometer device
Study NCT04635007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
Study NCT04635007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: 100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
Study NCT06032715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI (Brief Intervention)
Description: Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
Study NCT05195632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Hard capsule
Study NCT05195632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Film-coated tablet
Study NCT05694637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)
Description: Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline.